Cargando…

Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients

In radically resected gastric cancer the possibility to predict the site of relapse could be clinically relevant for the selection of post-surgical management. We previously showed that specific tumour integrins genotypes are independently associated with either peritoneal or hematogenous metastases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scartozzi, Mario, Loretelli, Cristian, Galizia, Eva, Mandolesi, Alessandra, Pistelli, Mirco, Bittoni, Alessandro, Giampieri, Riccardo, Faloppi, Luca, Bianconi, Maristella, Prete, Michela Del, Bianchi, Francesca, Belvederesi, Laura, Bearzi, Italo, Cascinu, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392267/ https://www.ncbi.nlm.nih.gov/pubmed/22808003 http://dx.doi.org/10.1371/journal.pone.0038192

Ejemplares similares

Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach
por: Bittoni, Alessandro, et al.
Publicado: (2013)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
por: Scartozzi, Mario, et al.
Publicado: (2012)

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients
por: Giampieri, Riccardo, et al.
Publicado: (2013)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

An intronic mutation in MLH1 associated with familial colon and breast cancer
por: Bianchi, F., et al.
Publicado: (2010)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
por: Scartozzi, Mario, et al.
Publicado: (2009)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
por: Bianconi, Maristella, et al.
Publicado: (2019)

Optimal management of resected gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2018)

N-VEGF, the Autoregulatory Arm of VEGF-A
por: Katsman, Marina, et al.
Publicado: (2022)

VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)

An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2021)

The Presence of VEGF Receptors on the Luminal Surface of Endothelial Cells Affects VEGF Distribution and VEGF Signaling
por: Stefanini, Marianne O., et al.
Publicado: (2009)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas
por: Corlan, Ana Silvia, et al.
Publicado: (2019)

Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs
por: Künnapuu, Jaana, et al.
Publicado: (2021)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy
por: Parveen, Amna, et al.
Publicado: (2019)

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
por: Bittoni, Alessandro, et al.
Publicado: (2021)

Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
por: Deissler, Heidrun L., et al.
Publicado: (2015)

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
por: Pritchard-Jones, R O, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_1tj4pesqridkjhkina270hce3u